上海轻度认知障碍的社区检测和管理:一种混合方法研究
Yuan Lu1, Dehua Yu2, Yvonne Wells3
1Department of Gerontology, Yangpu Hospital, Tongji University School of Medicine, 450 Tengyue Road,Tongji University Affiliated Yangpu Hospital, Shanghai 200090, China.
Health policy and planning
|April 24, 2025
概括
上海的初级保健在检测和管理轻度认知障碍 (MCI) 方面面临重大系统障碍. 应对这些挑战需要一种全面的系统方法,以改善痴呆症预防和健康衰老策略.
科学领域:
- 公共卫生 公共卫生
- 老年学是指老年学的学科.
- 医疗保健系统分析 医疗保健系统分析
背景情况:
- 痴呆症是健康衰老的公共卫生优先事项.
- 轻度认知障碍 (MCI) 的检测和管理对于减轻痴呆症日益增长的负担至关重要.
- 目前,MCI在初级保健机构中未得到充分的认可和管理.
研究的目的:
- 评估影响社区初级保健机构内MCI检测和管理的系统障碍.
- 确定阻碍MCI护理策略有效实施的具体障碍.
- 为在中国改善MCI护理的系统层面方法的开发提供信息.
主要方法:
- 一项混合方法研究,结合焦点组 (n=124) 与全科医生 (GPs),MCI患者,护理人员和卫生管理人员.
- 进行了两轮的Delphi国家调查 (n=22名专家),以就必要的系统条件达成共识.
- 一项问卷调查 (n=1253名全科医生) 评估了上海社区卫生中心 (CHC) 的知识,态度,做法和感知障碍.
主要成果:
- 系统障碍的八个主要主题被确定,包括缺乏自我管理支持,家庭和社区支持不足,医疗保健系统未准备好,服务交付问题,临床决策支持不足,病例管理不佳和信息系统不一致.
- 上海的初级保健系统没有为有效的MCI检测和管理提供设备.
- 内在和外在因素都阻碍了将MCI知识转化为可操作的护理.
结论:
- 需要在系统层面进行重大改革,以充分解决在中国的初级保健中MCI检测和管理的问题.
- 现有的初级保健基础设施和支持系统不足以满足MCI护理的需求.
- 必须采用多方面的系统方法,以克服已识别的障碍,并改善MCI患者的治疗结果.
更多相关视频
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
2.9K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.2K
相关概念视频
01:30Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
01:26Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:30Cognitive Development During Adulthood
72
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
72
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
110
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
110